Actavis Extends Specialty Drug Portfolio in US with Kadian®
According to IMS Health data, Kadian® brand product sales were $239million, for the 12 months ending June 2008.
Kadian® which is an extended release morphine sulfate product, is the first originator brand product to be marketed by Actavis US. The company anticipates marketing Kadian® only in the United States.
“The acquisition of Kadian is the latest step in Actavis’ strategy to expand our specialty drug portfolio and is well aligned with our emphasis on bringing complex controlled-release products to the marketplace,” said Actavis US CEO Doug Boothe. “Kadian has enjoyed significant market share and we are excited about its continued prospects as a drug that benefits many patients.”
Kadian®, used to treat moderate to severe chronic pain, is a currently marketed in 20mg, 30mg, 50mg, 60mg, 80mg, 100mg and 200mg dosage strength capsules. Kadian’s wide range of dosage strengths allows physicians to give patients more treatment options in managing their pain.
Actavis and its Elizabeth NJ facility have a long history with Kadian®. The product was originally developed and commercially launched at the facility. Actavis has been the contract manufacturer for Kadian® since 2005, when Actavis acquired Alpharma’s human generics business.
Actavis is one of the world’s leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. The company has operations in 40 countries, with 11,000 employees. The United States is the company’s single largest market. Actavis’ US operations are located in New Jersey, Maryland, North Carolina and Florida.
- Contact Information
- Hjördís Árnadóttir
- Director - External Communications
- Actavis Group
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.